Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2018 Publisher: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
Famvir 125 mg film-coated tablets.
Famciclovir 125 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, round film-coated tablet, biconvex, bevelled edges, debossed with “FV” on one side and “125” on the reverse side. |
Each film-coated tablet contains 125 mg of famciclovir.
Excipient with known effects: Each film-coated tablet contains 26.85 mg of lactose, anhydrous.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Famciclovir |
Famciclovir is the oral prodrug of penciclovir. Famciclovir is rapidly converted in vivo into penciclovir, which has in vitro activity against herpes simplex viruses (HSV types 1 and 2), varicella zoster virus (VZV), Epstein-Barr virus and cytomegalovirus. |
| List of Excipients |
|---|
|
Tablet core: Lactose, anhydrous Tablet coat: Hypromellose |
Famvir is supplied in PVC/PCTFE/Aluminium blister packs containing 10 tablets.
Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
PL 00101/0625
21 April 1995/08 July 2011
| Drug | Countries | |
|---|---|---|
| FAMVIR | Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, Hong Kong, Ireland, Italy, Japan, Malta, New Zealand, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
